[Therapy of hypertension in general practice with Renitec and Co-Renitec--analysis of an administration study].
In a user-observation study ("Anwendungsbeobachtung") it could be demonstrated that Renitec and Co-Renitec lowered elevated blood pressure but not sufficiently according to the WHO-criteria. It seems that the necessary dose titrations are not carried out in a daily routine. Furthermore it has to be stated that even widespread observation studies are not able to differentiate the properties of a drug. It remains to be considered whether more requirements on observation studies are necessary (regarding exact criteria for their design and increased monitoring) and should be implemented to improve the quality of data, although this would mean more time for the physician. Only under such conditions statements about rare side effects, influences of concomitant diseases and their treatments will be possible.
Magometschnigg
D
D
Institut für Hypertoniker, Wien.
Hitzenberger
G
G
D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001794:Blood Pressure / Q000187:drug effects; D004338:Drug Combinations; D004656:Enalapril / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide / Q000008:administration & dosage*; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D004338:Drug Combinations; D006852:Hydrochlorothiazide; D004656:Enalapril